Dermatology

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

This analysis assesses the positive predictive value of the ICD-10 code for vitiligo commonly used in electronic medical record-based research.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

This review of the month of September highlights some of the most significant dermatology headlines.

This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

This interview highlights the significance of remibrutinib's recent FDA approval for clinicians treating chronic spontaneous urticaria.

The first oral BTK inhibitor for CSU offers fast relief for patients uncontrolled on antihistamines and an alternative to injectable biologics.

The FDA has approved remibrutinib, a new oral treatment for chronic spontaneous urticaria, offering hope for patients unresponsive to antihistamines.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This Savvy Stories episode of the Skin of Color Savvy podcast features 4 speakers highlighting the SOCS Clinical Investigators Training Program.

These phase 3 data, released by MoonLake Immunotherapeutics, highlight week 16 results for patients with hidradenitis suppurativa using sonelokimab.

In this interview at EADV, Bernstein highlights dupilumab’s impact on urticaria activity in individuals with chronic spontaneous urticaria (CSU).

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

This interview highlighted findings on actinic keratosis following treatment with tirbanibulin.

This September 22 Savvy Conversations episode features a conversation on vitiligo and its impact on patients of diverse skin types.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Ruxolitinib cream shows promising results in prurigo nodularis, with significant symptom improvements and strong safety profiles.

These data from the ECZTRA 3 and ECZTEND trials highlight tralokinumab’s impact on patients with atopic dermatitis long-term.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.